Last reviewed · How we verify

NCT07312526

Shanghai Clinical Cohort - Esophageal Cancer

Completed Last updated 15 April 2026
What this trial tests

trial testing esophagectomy in Esophageal Cancer in 2,116 participants. Completed in 31 March 2026.

Timeline
1 July 2025
Primary endpoint
31 March 2026
31 March 2026

Quick facts

Lead sponsorShanghai Chest Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,116
Start date1 July 2025
Primary completion31 March 2026
Estimated completion31 March 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Chest Hospital

Who can join

Eligibility, any sex, with Esophageal Cancer or Esophagectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of esophagectomy

Trials testing the same drug.

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07312526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing